Glucosylceramide modulates endolysosomal pH in Gaucher disease
- 1 June 2013
- journal article
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 109 (2) , 194-200
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Caveolin targeting to late endosome/lysosomal membranes is induced by perturbations of lysosomal pH and cholesterol contentMolecular Biology of the Cell, 2012
- Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic responseBlood, 2011
- Hyperacidification of Trans‐Golgi Network and Endo/Lysosomes in Melanocytes by Glucosylceramide‐Dependent V‐ATPase ActivityTraffic, 2011
- Mucolipin-3 Regulates Luminal Calcium, Acidification, and Membrane Fusion in the Endosomal PathwayJournal of Biological Chemistry, 2011
- Lysosomal fusion and SNARE function are impaired by cholesterol accumulation in lysosomal storage disordersThe EMBO Journal, 2010
- A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1Blood, 2010
- Membrane traffic and turnover in TRP-ML1–deficient cells: a revised model for mucolipidosis type IV pathogenesisJournal of Experimental Medicine, 2008
- Pre- and post-Golgi translocation of glucosylceramide in glycosphingolipid synthesisJournal of Cell Biology, 2007
- Mutation of β-glucosidase 2 causes glycolipid storage disease and impaired male fertilityJournal of Clinical Investigation, 2006
- Glucosylceramide synthase is an essential regulator of pathogenicity of Cryptococcus neoformansJournal of Clinical Investigation, 2006